Tango Therapeutics, Inc.
Symbol: TNGX (NASDAQ)
6.40
▲ (0.68%) 0.043
Company Description:
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Key Stats
- Today's Open: $6.36
- Today's High: $6.569
- Today's Low: $6.365
- Today's Volume: 119.92K
- Yesterday Close: $6.36
- Yesterday High: $6.85
- Yesterday Low: $6.25
- Yesterday Volume: 1.36M
- Last Min Volume: 1.31K
- Last Min High: $6.412
- Last Min Low: $6.406
- Last Min VWAP: $6.40932
Company Profile
- Name: Tango Therapeutics, Inc.
- Website: https://www.tangotx.com
- Listed Date: 2021-08-11
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0001819133
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $707.62M
- Round Lot: 100
- Outstanding Shares: 111.26M
- Asset Type: CS
RECENT FILINGS FOR TNGX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-09 | 4 | View |
| 2025-09-08 | 144 | View |
| 2025-09-05 | 144 | View |
| 2025-08-26 | 4 | View |
| 2025-08-25 | 8-K | View |
| 2025-08-22 | 144 | View |
| 2025-08-21 | 4 | View |
| 2025-08-19 | 144 | View |
| 2025-08-14 | SCHEDULE 13G | View |
| 2025-08-13 | SCHEDULE 13G/A | View |
| 2025-08-12 | SCHEDULE 13G | View |
| 2025-08-05 | 10-Q | View |
| 2025-08-05 | 8-K | View |
| 2025-07-17 | SCHEDULE 13G | View |
| 2025-06-13 | SCHEDULE 13G | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
Latest News on TNGX